![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Low Proportion of Individuals Develop Metabolic Syndrome (MetS) or Hepatic Fibrosis After Switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed Patients: A Post Hoc Metabolic Analysis
|
|
|
IAS 2021 July 18-22
Keith Dunn,1 Amanda Gibson,1,* Erika Van Landuyt,2 Shubin Sheng,3 Donghan Luo,3 Jiyun Cai,3 Bryan Baugh4
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, Beerse, Belgium; 3Janssen Research & Development, LLC, Titusville, NJ, USA; 4Janssen Research & Development, LLC, Raritan, NJ, USA.
![0721211](../images/072121/072121-2/0721211.gif)
![0721212](../images/072121/072121-2/0721212.gif)
![0721213](../images/072121/072121-2/0721213.gif)
![0721214](../images/072121/072121-2/0721214.gif)
![0721215](../images/072121/072121-2/0721215.gif)
![0721216](../images/072121/072121-2/0721216.gif)
![0721217](../images/072121/072121-2/0721217.gif)
![0721218](../images/072121/072121-2/0721218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|